Don’t Count on 23andMe to Detect Most Breast Cancer Risks, Study Warns

The DNA testing company, which has 10 million customers, misses nearly 90 percent of people with risky BRCA mutations. It says the criticism is overblown. HEATHER MURPHY https://nyti.ms/2GlsXBT http://bit.ly/2UCmRXH The New York Times Health Genetics and Heredity, Tests (Medical), Breast Cancer, Ovarian Cancer April 16, 2019 at 12:00AM